New SUSTAIN-6 Data Could Explain Retinopathy Worsening

Source: Medscape

Monday, June 12, 2017 | Medical Studies


New data from the Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes (SUSTAIN-6) provide a plausible explanation for the worsening retinopathy seen among patients taking the investigational glucagonlike-peptide 1 (GLP-1) agonist semaglutide (Novo Nordisk), suggesting that the problem is likely due to rapid glucose-lowering in already-vulnerable patients, rather than a drug-specific effect.

Open in New Window

Comments

You must be logged in to leave a comment.